Work

Merged pdf from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Year: 2023

Type: other

Abstract: Article File and Figures

DOI: 10.1158/0008-5472.22419945

Authors: Claudia Capparelli, Timothy J. Purwin, Shea A. Heilman, Inna Chervoneva, Peter A. McCue, Adam C. Berger, Michael A. Davies, Jeffrey E. Gershenwald, Clemens Krepler, Andrew E. Aplin

Institutions: Thomas Jefferson University, The University of Texas MD Anderson Cancer Center, Sidney Kimmel Cancer Center, The Wistar Institute

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Melanoma Research Alliance, Yale University, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, University of Miami, Memorial Sloan-Kettering Cancer Center, Thomas Jefferson University, National Institutes of Health, Genentech, University of Texas MD Anderson Cancer Center, National Cancer Institute

Awards: G132965223, G1619438925, G1727840030, G4595681443, G4892117850, G5016707533, Mutant BRAF-regulated transcription factors in melanoma progression, G7066338595, Translational Research in Cancer

OpenAlex ID: W4361876489

Cites: 52

Cited by:

Related to: 10